FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783202319> ?p ?o ?g. }

• W2783202319 endingPage "415" @default.
• W2783202319 startingPage "407" @default.
• W2783202319 abstract "Active surveillance (AS) aims to reduce overtreatment of low-risk prostate cancer (PC). Incorporating multiparametric magnetic resonance imaging (mp-MRI) and MR-guided biopsy (MRGB) in an AS protocol might contribute to more accurate identification of AS candidates.To evaluate the value of 3T mp-MRI and MRGB in PC patients on AS at inclusion and after 12-mo follow-up.Patients with cT1c-cT2 PC, prostate-specific antigen (PSA) ≤10ng/ml, PSA density <0.2ng/ml/ml, and Gleason scores (GSs) of ≤6 and ≤2 positive biopsy cores were included and followed in an AS protocol including mp-MRI and MRGB. The mp-MRI and MRGB were performed at <3 and 12 mo after diagnosis. Reclassification was defined as GS >6, >2 positive cores at repeat transrectal ultrasound-guided biopsy (TRUSGB), presence of PC in >3 separate cancer foci upon both MRGB and TRUSGB, or cT3 tumor on mp-MRI.Reclassification rates, treatment after discontinuation, and outcome on radical prostatectomy after discontinuing AS were reported. Uni- and multivariate analyses were performed to identify predictors of reclassification after 1 yr.From 2009 to 2013, a total of 111 of 158 patients were consecutively and prospectively included. Around initial diagnosis, 36 patients were excluded from the study protocol; mp-MRI+MRGB reclassified 25/111 (23%) patients, and 11 patients were excluded at own request. Reasons for reclassification were as follows: GS upgrade (15/25, 60%); cT3 disease (3/25, 12%); suspicion of bone metastases (1/25, 4%); and multifocal disease upon MRGB (6/25, 24%). Repeat examinations after 1 yr showed reclassification in 33/75 patients (44%). Reasons were the following: GS upgrade upon TRUSGB (9/33, 27%); volume progression upon TRUSGB (9/33, 27%); cT3 disease upon mp-MRI (1/33, 3%); GS upgrade upon MRGB (1/33, 3%); volume progression upon MRGB (1/33, 3%); multifocal disease upon MRGB (2/33, 6%); and upgrade or upstage upon both TRUSGB and MRGB (10/33, 30%). On logistic regression analysis, the presence of cancer at initial mp-MRI and MRGB examinations was the only predictor of reclassification after 1 yr (odds ratio 5.9, 95% confidence interval 2.0-17.6).Although mp-MRI and MRGB are of additional value in the evaluation of PC patients on AS, the value of mp-MRI after 1 yr was limited. As a considerable percentage of GS ≥7 PC after 1 yr was detected only by TRUSGB, TRUSGB cannot be omitted yet.More aggressive tumors are detected if low-risk prostate cancer patients are additionally monitored by magnetic resonance imaging. However, some high-grade tumors are detected only by transrectal ultrasound-guided biopsy." @default.
• W2783202319 created "2018-01-26" @default.
• W2783202319 creator A5006267969 @default.
• W2783202319 creator A5011481748 @default.
• W2783202319 creator A5022119080 @default.
• W2783202319 creator A5024003056 @default.
• W2783202319 creator A5024493292 @default.
• W2783202319 creator A5028399139 @default.
• W2783202319 creator A5030962499 @default.
• W2783202319 creator A5036052565 @default.
• W2783202319 creator A5040920764 @default.
• W2783202319 creator A5043439079 @default.
• W2783202319 creator A5053996737 @default.
• W2783202319 creator A5085138741 @default.
• W2783202319 date "2019-05-01" @default.
• W2783202319 modified "2023-10-17" @default.
• W2783202319 title "Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging–guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up" @default.
• W2783202319 cites W1516346188 @default.
• W2783202319 cites W1827911007 @default.
• W2783202319 cites W1966441258 @default.
• W2783202319 cites W1973798930 @default.
• W2783202319 cites W1978219824 @default.
• W2783202319 cites W1984737078 @default.
• W2783202319 cites W1992680251 @default.
• W2783202319 cites W2020439157 @default.
• W2783202319 cites W2032956975 @default.
• W2783202319 cites W2039897637 @default.
• W2783202319 cites W2061687418 @default.
• W2783202319 cites W2070349594 @default.
• W2783202319 cites W2095284457 @default.
• W2783202319 cites W2098226918 @default.
• W2783202319 cites W2105250521 @default.
• W2783202319 cites W2110569728 @default.
• W2783202319 cites W2112201228 @default.
• W2783202319 cites W2117658580 @default.
• W2783202319 cites W2131988302 @default.
• W2783202319 cites W2138320929 @default.
• W2783202319 cites W2139566281 @default.
• W2783202319 cites W2143612480 @default.
• W2783202319 cites W2153601964 @default.
• W2783202319 cites W2161701122 @default.
• W2783202319 cites W2164364841 @default.
• W2783202319 cites W2284433611 @default.
• W2783202319 cites W2336226172 @default.
• W2783202319 cites W2439583849 @default.
• W2783202319 cites W2570618306 @default.
• W2783202319 cites W2752380359 @default.
• W2783202319 cites W4243698290 @default.
• W2783202319 doi "https://doi.org/10.1016/j.euf.2017.12.008" @default.
• W2783202319 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29331622" @default.
• W2783202319 hasPublicationYear "2019" @default.
• W2783202319 type Work @default.
• W2783202319 sameAs 2783202319 @default.
• W2783202319 citedByCount "22" @default.
• W2783202319 countsByYear W27832023192018 @default.
• W2783202319 countsByYear W27832023192020 @default.
• W2783202319 countsByYear W27832023192021 @default.
• W2783202319 countsByYear W27832023192022 @default.
• W2783202319 countsByYear W27832023192023 @default.
• W2783202319 crossrefType "journal-article" @default.
• W2783202319 hasAuthorship W2783202319A5006267969 @default.
• W2783202319 hasAuthorship W2783202319A5011481748 @default.
• W2783202319 hasAuthorship W2783202319A5022119080 @default.
• W2783202319 hasAuthorship W2783202319A5024003056 @default.
• W2783202319 hasAuthorship W2783202319A5024493292 @default.
• W2783202319 hasAuthorship W2783202319A5028399139 @default.
• W2783202319 hasAuthorship W2783202319A5030962499 @default.
• W2783202319 hasAuthorship W2783202319A5036052565 @default.
• W2783202319 hasAuthorship W2783202319A5040920764 @default.
• W2783202319 hasAuthorship W2783202319A5043439079 @default.
• W2783202319 hasAuthorship W2783202319A5053996737 @default.
• W2783202319 hasAuthorship W2783202319A5085138741 @default.
• W2783202319 hasConcept C121608353 @default.
• W2783202319 hasConcept C126322002 @default.
• W2783202319 hasConcept C126838900 @default.
• W2783202319 hasConcept C126894567 @default.
• W2783202319 hasConcept C143409427 @default.
• W2783202319 hasConcept C2775934546 @default.
• W2783202319 hasConcept C2776235491 @default.
• W2783202319 hasConcept C2779466945 @default.
• W2783202319 hasConcept C2780192828 @default.
• W2783202319 hasConcept C2781406297 @default.
• W2783202319 hasConcept C2989005 @default.
• W2783202319 hasConcept C71924100 @default.
• W2783202319 hasConceptScore W2783202319C121608353 @default.
• W2783202319 hasConceptScore W2783202319C126322002 @default.
• W2783202319 hasConceptScore W2783202319C126838900 @default.
• W2783202319 hasConceptScore W2783202319C126894567 @default.
• W2783202319 hasConceptScore W2783202319C143409427 @default.
• W2783202319 hasConceptScore W2783202319C2775934546 @default.
• W2783202319 hasConceptScore W2783202319C2776235491 @default.
• W2783202319 hasConceptScore W2783202319C2779466945 @default.
• W2783202319 hasConceptScore W2783202319C2780192828 @default.
• W2783202319 hasConceptScore W2783202319C2781406297 @default.
• W2783202319 hasConceptScore W2783202319C2989005 @default.
• W2783202319 hasConceptScore W2783202319C71924100 @default.
• W2783202319 hasIssue "3" @default.
• W2783202319 hasLocation W27832023191 @default.

• next